Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trimecaine is a local anesthetic of the amide group and a Class Ib antiarrhythmic agent, primarily developed and utilized in Central and Eastern Europe (notably the former Czechoslovakia). As a derivative of lidocaine, it functions by reversibly blocking voltage-gated sodium channels in neuronal membranes, thereby inhibiting the initiation and conduction of nerve impulses to provide regional anesthesia. In cardiology, trimecaine is used to treat and prevent ventricular arrhythmias, particularly those occurring in the setting of acute myocardial infarction, by shortening the action potential duration and effective refractory period in Purkinje fibers. It is characterized by a rapid onset of action and is administered via various routes including infiltration, topical, and intravenous injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trimecaine.